HomeMedlineStudy Demonstrates New Standard of Care for Accurately Measuring Intra-Abdominal Pressure in Critical Care Patients

Study Demonstrates New Standard of Care for Accurately Measuring Intra-Abdominal Pressure in Critical Care Patients


New medical device, Accuryn®, has potential to enhance reliability and decrease time required to measure intra-abdominal pressure

The prevalence of intra-abdominal hypertension (IAH) in the critically ill is reported to be as high as 50 percent and is a significant cause of abdominal compartment syndrome (ACS), morbidity and mortality.

Diagnosis requires an accurate, reliable and consistent standardized methodology for measuring intra-abdominal pressure (IAP). The accuracy of the intra-vesical pressure (IVP) method, the current standard-of-care measurement method, is hindered by “self-assembly” set-up, which is performed manually and introduces non-standardized construction, clinical technique and quality control challenges. It is often time-consuming, leads to errors and can put patients at risk for infection.

A recent study demonstrates a new method for automatically measuring IAP, the Accuryn Monitoring System, gives the same precision of accuracy as commercially-available methods while obtained more easily with a simple push of a button. Results will be shared at the 8th World Congress of the Abdominal Compartment Society meeting, June 15 – 17 in Banff, Alberta, Canada.

A benchtop study compared pressure measured by the Accuryn Monitoring System to a commercially available standard-of-care intra-vesical pressure (IVP) device. The Accuryn device had a higher measurement accuracy compared to the IVP device and the same precision compared to the IVP device across repeat measurements.

 

Dr. Daniel Burnett, chief executive officer of Potrero Medical, the maker of Accuryn, and adjunct professor at the University of California at San Francisco, “This study paves the way for industry discussions around the utility of continuous IAP monitoring. IAP measurements that accurately diagnose IAH and abdominal compartment syndrome historically have been significantly difficult to obtain. By simplifying the process and enhancing accuracy, Accuryn has the potential to guide earlier diagnoses and interventions to improve patient outcomes.”

The company has partnered with Potrero Medical, the maker of Accuryn, to bring the device to market and advance real-time monitoring for critically ill patients.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy